Skip to main content
Top
Published in: Journal of Endocrinological Investigation 9/2014

01-09-2014 | Original Article

Cardiovascular risk factors and adipocytokines levels after two hypocaloric diets with different fat distribution in obese subjects and rs6923761 gene variant of glucagon-like peptide 1 receptor

Authors: Daniel Antonio de Luis, Rocío Aller, Olatz Izaola, R. Bachiller, D. Pacheco

Published in: Journal of Endocrinological Investigation | Issue 9/2014

Login to get access

Abstract

Background

The role of GLP-1 R variants on body weight response after dietary intervention is unclear.

Objective

Our aim was to evaluate the effect of this polymorphism on cardiovascular risk factors, adipokine levels and weight loss secondary to a high monounsaturated fat vs. a high polyunsaturated fat hypocaloric diets in obese subjects.

Design

391 obese subjects were randomly allocated to one of these two diets for a period of 3 months; diet M (high monounsaturated fat hypocaloric diet) and diet P (high polyunsaturated (PUFAs) fat hypocaloric diet).

Results

Two hundred and twelve patients (54.2 %) had the genotype GG (wild group) and 179 (45.8 %) patients had the next genotypes; GA (146 patients, 37.3 %) or AA (33 patients, 8.7 %) (Mutant group). With both diets and in wild-type and mutant-type groups, BMI, weight, fat mass, waist circumference and systolic blood pressure decreased. Anthropometric parameters were higher in non-A-allele carriers than A-allele carriers. With both diets and in both genotypes, leptin, insulin levels and HOMA decreased. With the diet P and in wild genotype, total cholesterol and LDL-cholesterol levels decreased, too.

Conclusion

Our data showed a lack of association of rs6923761 GLP-1 R polymorphism with weight loss after a high monounsaturated fat and a high polyunsaturated fat hypocaloric diets. Better anthropometric parameters in obese subjects with the mutant allele (A) of rs6923761 GLP-1 R polymorphism were observed. Insulin levels and HOMA decreased in non-A carriers.
Literature
2.
go back to reference Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430–441PubMedCrossRef Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430–441PubMedCrossRef
3.
go back to reference Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968–2978PubMed Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968–2978PubMed
4.
go back to reference Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, Kanatsuka A (2004) Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract 66:63–69PubMedCrossRef Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, Kanatsuka A (2004) Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract 66:63–69PubMedCrossRef
5.
go back to reference Sathananthan A, Dalla C, Micheletto F, Zinsmeister A, Camilleri M, Giesler P (2010) Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes Care 33:2074–2076PubMedCentralPubMedCrossRef Sathananthan A, Dalla C, Micheletto F, Zinsmeister A, Camilleri M, Giesler P (2010) Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes Care 33:2074–2076PubMedCentralPubMedCrossRef
6.
go back to reference Matsuda M, Shimomura I, Sata M (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487–37491PubMedCrossRef Matsuda M, Shimomura I, Sata M (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487–37491PubMedCrossRef
7.
go back to reference Kumada M, Kihara S, Sumitsuji S (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89PubMedCrossRef Kumada M, Kihara S, Sumitsuji S (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89PubMedCrossRef
8.
go back to reference Steppan CM, Bailey ST, Bhat S (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312PubMedCrossRef Steppan CM, Bailey ST, Bhat S (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312PubMedCrossRef
9.
go back to reference Adipocytokines Matsuzawa Y (2005) Emerging therapeutic targets. Curr Atheroscler Rep 7:58–62CrossRef Adipocytokines Matsuzawa Y (2005) Emerging therapeutic targets. Curr Atheroscler Rep 7:58–62CrossRef
10.
go back to reference Mataix J, Mañas M (2003) Tablas de composición de alimentos españoles. University of Granada, Granada Mataix J, Mañas M (2003) Tablas de composición de alimentos españoles. University of Granada, Granada
11.
go back to reference Lubrano V, Cocci F, Battaglia D (2005) Usefulness of high –sensitivity IL6 measurement for clinical characterization of patients with coronary artery disease. J Clin Lab Anal 19:110–114PubMedCrossRef Lubrano V, Cocci F, Battaglia D (2005) Usefulness of high –sensitivity IL6 measurement for clinical characterization of patients with coronary artery disease. J Clin Lab Anal 19:110–114PubMedCrossRef
12.
go back to reference Duart MJ, Arroyo CO, Moreno JL (2002) Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 40:1161–1167CrossRef Duart MJ, Arroyo CO, Moreno JL (2002) Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 40:1161–1167CrossRef
13.
go back to reference Mathews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–414CrossRef Mathews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–414CrossRef
14.
go back to reference Pfutzner A, Langefeld M, Kunt T (2003) Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 49:571–576PubMed Pfutzner A, Langefeld M, Kunt T (2003) Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 49:571–576PubMed
15.
go back to reference Meier U, Gressner M (2004) Endocrine regulation of energy metabolis: review of pathobiochemical and clinical chemical aspects of leptin, Ghrelin, adiponectin, and resistin. Clin Chem 50:1511–1525PubMedCrossRef Meier U, Gressner M (2004) Endocrine regulation of energy metabolis: review of pathobiochemical and clinical chemical aspects of leptin, Ghrelin, adiponectin, and resistin. Clin Chem 50:1511–1525PubMedCrossRef
16.
go back to reference Suominen P (2004) Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clin Chem 50:219–221PubMedCrossRef Suominen P (2004) Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clin Chem 50:219–221PubMedCrossRef
17.
go back to reference Fortin JP, Schroeder J, Zhu Y, Beinborn M, Kopin A (2010) Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Ther 332:274–280PubMedCentralPubMedCrossRef Fortin JP, Schroeder J, Zhu Y, Beinborn M, Kopin A (2010) Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Ther 332:274–280PubMedCentralPubMedCrossRef
18.
go back to reference Barash A, de grado T, Cano O, Bordiu E (2012) Effect of GLP-1 receptor variants on weight loss and comorbidities in obese patients under bariatric surgery. In: 54 Congress of Endocrinology Society Madrid (Abstract) Barash A, de grado T, Cano O, Bordiu E (2012) Effect of GLP-1 receptor variants on weight loss and comorbidities in obese patients under bariatric surgery. In: 54 Congress of Endocrinology Society Madrid (Abstract)
19.
go back to reference Scrocchi LA, Marshall BA, Cook SM, Brubaker DJ (1998) Identification of GLP-1 actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47:632–639PubMedCrossRef Scrocchi LA, Marshall BA, Cook SM, Brubaker DJ (1998) Identification of GLP-1 actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47:632–639PubMedCrossRef
Metadata
Title
Cardiovascular risk factors and adipocytokines levels after two hypocaloric diets with different fat distribution in obese subjects and rs6923761 gene variant of glucagon-like peptide 1 receptor
Authors
Daniel Antonio de Luis
Rocío Aller
Olatz Izaola
R. Bachiller
D. Pacheco
Publication date
01-09-2014
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 9/2014
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-014-0116-3

Other articles of this Issue 9/2014

Journal of Endocrinological Investigation 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine